Luye Pharma Group today announced that BA1105, a novel antibody developed by its subsidiary Boan Biotech, has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Prod...
Luye Pharma Group today announced that LY03015, a next-generation Vesicular Monoamine Transporter 2 (VMAT2) inhibitor, has been approved by the Centre for Drug Evaluation (CDE) of China’s Nation...
Research results from a study into Luye Pharma’s in-house developed LY03015, a next-generation vesicular monoamine transporter 2 (VMAT2) inhibitor, were recently published in the European Journa...
September 27, 2021, Shanghai, China – Luye Pharma Group today announced that Dulaglutide Injection (BA5101) developed in-house by Boan Biotech, a subsidiary of the Group, has obtained approval f...
September 26, 2021, Boston, USA - Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific anti...
September 23,2021. Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) has been granted by the UK’...
Luye Pharma Group announced today that a Phase III clinical trial of its innovative formulation for the treatment of prostate cancer, Goserelin Acetate Extended-release Microspheres for Injection (LY0...
Luye Pharma Group today announced that Boyounuo (Bevacizumab Injection), an oncology biologic developed in-house by its subsidiary Boan Biotech, has been approved by China’s National Medical Pro...
The global COVID-19 pandemic poses a serious threat to physical health and has wide-ranging implications for mental health worldwide. At the third Asia Pacific Psychiatry Symposium, held online on Jun...
Luye Pharma Group’s subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) inAntibody Therapeutics...
TOP